Alpine Immune Sciences, Inc.

NasdaqGM:ALPN 株式レポート

時価総額:US$4.5b

Alpine Immune Sciences 過去の業績

過去 基準チェック /06

Alpine Immune Sciencesの収益は年間平均-6.1%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間19.1% 51.3%割合で 増加しています。

主要情報

-6.1%

収益成長率

17.6%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率51.3%
株主資本利益率-11.1%
ネット・マージン-65.2%
前回の決算情報31 Mar 2024

最近の業績更新

Recent updates

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Apr 11

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Mar 21
Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Mar 20
Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Mar 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Feb 07
Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Dec 19
Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Sep 23
We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

May 11
Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Dec 12
Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Alpine Immune Sciences drops 13% after hours on $100M stock offering

Sep 20

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Aug 09
Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Alpine: Rest Before Rallying Again

Apr 25

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Apr 12
Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Sep 18
Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Aug 18
Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

収支内訳

Alpine Immune Sciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGM:ALPN 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 2457-37240
31 Dec 2359-32220
30 Sep 2331-57200
30 Jun 2329-59190
31 Mar 2326-64190
31 Dec 2230-58180
30 Sep 2232-54180
30 Jun 2232-54170
31 Mar 2234-47160
31 Dec 2123-50150
30 Sep 2125-42130
30 Jun 2118-34120
31 Mar 2111-33120
31 Dec 209-28110
30 Sep 205-28100
30 Jun 203-33100
31 Mar 203-3590
31 Dec 192-4290
30 Sep 191-47100
30 Jun 191-4890
31 Mar 190-4490
31 Dec 181-3680
30 Sep 181-3070
30 Jun 181-1570
31 Mar 181-1160
31 Dec 172-850
30 Sep 172-540
30 Jun 173-720
31 Mar 173-320
31 Dec 163-110
31 Dec 150000

質の高い収益: ALPNは現在利益が出ていません。

利益率の向上: ALPNは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: ALPNは利益が出ておらず、過去 5 年間で損失は年間6.1%の割合で増加しています。

成長の加速: ALPNの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ALPNは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。


株主資本利益率

高いROE: ALPNは現在利益が出ていないため、自己資本利益率 ( -11.07% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘